RAC1 and cancer: Importantly, aberrant Rac1 activation also occurs in other deadly human diseases (most notably cancer and cardiovascular disease), so that development of clinically-suitable Rac1 inhibitors continues to be a highly pursued goal with potential implications for the field of HIV therapeutics [132,133,134,135].